Santarus, Inc. : Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
04/10/2012| 04:05am US/Eastern
Recommend:
Santarus, Inc. (NASDAQ: SNTS) today announced the appointment of
Alessandro E. Della Chà and Matthew W. Strobeck, Ph.D., to the company's
board of directors, increasing its board membership to nine.
"We welcome our new board members and look forward to drawing on their
industry, business and corporate expertise as we continue to build
Santarus into a premier specialty biopharmaceutical company," said David
F. Hale, chairman of the board of Santarus. "Alex also brings us an
international perspective and a strong relationship with a key corporate
partner. Matt has an impressive background in life sciences and valuable
financial experience, including his prior role with Westfield Capital
Management."
Since 1997, Mr. Della Chà has been a senior partner of Studio Legale
Edoardo Ricci e Associati, a leading boutique commercial law firm in
Milan, Italy, and has served as a co-managing director of the firm since
2003. Mr. Della Chà has represented Italian companies and banks in
litigation, commercial and bankruptcy matters, with significant
experience in the fields of capital market transactions, IPOs, private
placements, corporate governance issues and corporate restructurings. He
currently serves as a director of Cosmo Pharmaceuticals S.p.A. Mr. Della
Chà holds a degree in law from the Università degli Studi di Milano and
a Masters in European commercial law from the University of Leicester,
England.
Dr. Strobeck was a partner, member of the management committee and
member of the advisory board of Westfield Capital Management from 2008
to 2011. Dr. Strobeck organized and led the purchase of Westfield in
2008 from Boston Private Bank, and prior to this transaction he was a
member of the Westfield investment team since 2003. Dr. Strobeck
currently serves as a member of the board of directors of Metabolix,
Inc. Dr. Strobeck received a B.S. in biology from St. Lawrence
University and a Ph.D. in cellular and molecular biology from the
University of Cincinnati. In addition, Dr. Strobeck received an S.M.
from the Harvard University-MIT Health Sciences Technology Program and
an S.M. from the MIT Sloan School of Management.
About Santarus
Santarus, Inc. is a specialty biopharmaceutical company focused on
acquiring, developing and commercializing proprietary products that
address the needs of patients treated by physician specialists. The
company's current commercial efforts are focused on GLUMETZA®
(metformin hydrochloride extended release tablets) and CYCLOSET®
(bromocriptine mesylate) tablets, which are indicated as adjuncts to
diet and exercise to improve glycemic control in adults with type 2
diabetes, and on FENOGLIDE®
(fenofibrate) tablets, which is indicated as an adjunct to diet to
reduce high cholesterol.
Santarus has a diverse product development pipeline. A New Drug
Application for UCERIS™ (budesonide) tablets for induction of
remission of mild to moderate active ulcerative colitis is under review
by the FDA with a response expected in October 2012. The pipeline also
includes two late-stage investigational drugs: RHUCIN®
(recombinant human C1 inhibitor) for treatment of acute attacks of
hereditary angioedema and rifamycin SV MMX® for treatment of
travelers' diarrhea, both of which are being evaluated in Phase III
clinical studies. In addition, the company's investigational monoclonal
antibody, SAN-300, is being evaluated in a Phase I clinical program.
More information about Santarus is available at www.santarus.com.
Santarus cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements. The inclusion of forward-looking statements should
not be regarded as a representation by Santarus that any of its plans
will be achieved. Actual results may differ materially from those
set forth in this release due to the risks and uncertainties inherent in
Santarus' business, including, without limitation: difficulties or
delays in development, testing, manufacturing and marketing of, and
obtaining and maintaining regulatory approvals for, Santarus' products;
and other risks detailed in Santarus' prior press releases as well as in
public periodic filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Santarus undertakes no obligation to revise or
update this news release to reflect events or circumstances after the
date hereof. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.
Santarus®, FENOGLIDE®
and UCERIS™ are trademarks of Santarus, Inc.
GLUMETZA® is a trademark of Biovail
Laboratories International S.r.l. licensed exclusively in the United
States to Depomed, Inc. CYCLOSET® is a
trademark of VeroScience LLC. MMX® is a
trademark of Cosmo Technologies Limited. RHUCIN®
is a trademark of Pharming Group NV.
COMPANY CONTACT:
Santarus, Inc.
Martha L. Hough
VP
Finance & Investor Relations
858-314-5824
or
Debra P.
Crawford
Chief Financial Officer
858-314-5708
or
INVESTOR
CONTACT:
LHA
Jody Cain or Bruce Voss, 310-691-7100
jcain@lhai.com
bvoss@lhai.com
@LHA_IR_PR
© Business Wire 2012
Recommend :
